CJC-1295 without DAC 5 mg + IPA 5 mg

CJC-1295 without DAC + Ipamorelin blend pairs a modified GRF peptide with the five-residue peptide Ipamorelin.

Research overview

CJC-1295 without DAC + Ipamorelin blend contains two peptides studied in endocrine research. The first component is the 29-residue modified GRF chain with a free amino terminus and an amidated carboxyl end, without the DAC extension. Its cited reference concerns albumin-binding derivatives of hGRF(1-29). Jetté and colleagues investigated conjugation through albumin Cys34, stability against dipeptidylpeptidase-IV, and growth hormone secretion in cultured rat anterior pituitary cells. Their rat experiments included Western blot analysis of plasma. These experiments examined albumin-binding derivatives and their conjugates, not the component without DAC [1].

Ipamorelin is a pentapeptide containing the nonstandard residues Aib, D-2Nal and D-Phe, together with histidine and lysine, and an amidated carboxyl end. Its cited characterisation used primary rat pituitary cells and animal models including rats and swine. In the cultured cells, researchers measured growth hormone release and used pharmacological antagonists to distinguish a GHRP-like receptor pathway from GHRH signalling. The chemistry programme identified Ipamorelin in a series lacking the central Ala-Trp dipeptide of GHRP-1 [2].

Neither reference examines this combination of CJC-1295 without DAC and Ipamorelin. They do not establish a joint response, interaction or shared mechanism for the two-component blend [1][2].

Laboratory storage and handling

Store the closed vial under the temperature conditions stated in the lot documentation, protected from light and moisture. Before opening, allow the vial to reach room temperature to limit condensation on the material. Minimise repeated freezing and thawing of laboratory stocks, retain the lot identifier in experimental records and wear standard laboratory protective equipment.

Questions about CJC-1295 without DAC + Ipamorelin blend

References

1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
2. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822

Identity data checked on 2026-09-24. Literature summaries describe published research models and are not specifications of any product lot.